RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Dicerna Pharmaceuticals Stock

Dicerna Pharmaceuticals Revenue 2024

Dicerna Pharmaceuticals Revenue

170.98 M USD

Ticker

DRNA

ISIN

US2530311081

WKN

A1XCYU

In 2024, Dicerna Pharmaceuticals's sales reached 170.98 M USD, a -2.8% difference from the 175.91 M USD sales recorded in the previous year.

The Dicerna Pharmaceuticals Revenue history

YEARREVENUE (undefined USD)GROSS MARGIN (%)
2025e169.51-
2024e170.98-
2023e175.91-
2022e205.94-
2021e182.47-
2020164.3-
201923.9-
20186.2-
20171-
20160.3-
20150.2-
2014--
2013--
20127-
20117.9-

Dicerna Pharmaceuticals Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Dicerna Pharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Dicerna Pharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Dicerna Pharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Dicerna Pharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Dicerna Pharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Dicerna Pharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Dicerna Pharmaceuticals’s growth potential.

Dicerna Pharmaceuticals Revenue, EBIT and net profit per share

DateDicerna Pharmaceuticals RevenueDicerna Pharmaceuticals EBITDicerna Pharmaceuticals Net Income
2025e169.51 M undefined-113.9 M undefined-111.8 M undefined
2024e170.98 M undefined-160.32 M undefined-149.22 M undefined
2023e175.91 M undefined-230.18 M undefined-203.16 M undefined
2022e205.94 M undefined-167.18 M undefined-154.87 M undefined
2021e182.47 M undefined-139.05 M undefined-130.17 M undefined
2020164.3 M undefined-113.2 M undefined-112.7 M undefined
201923.9 M undefined-128.2 M undefined-120.5 M undefined
20186.2 M undefined-61.3 M undefined-88.9 M undefined
20171 M undefined-51.7 M undefined-60.2 M undefined
2016300,000 undefined-59.7 M undefined-59.5 M undefined
2015200,000 undefined-63 M undefined-62.8 M undefined
20140 undefined-45.1 M undefined-47.9 M undefined
20130 undefined-17.4 M undefined-18.5 M undefined
20127 M undefined-9.3 M undefined-10.1 M undefined
20117.9 M undefined-7.6 M undefined-8.6 M undefined

Dicerna Pharmaceuticals stock margins

The Dicerna Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Dicerna Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Dicerna Pharmaceuticals.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Dicerna Pharmaceuticals's sales revenue. A higher gross margin percentage indicates that the Dicerna Pharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Dicerna Pharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Dicerna Pharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Dicerna Pharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Dicerna Pharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Dicerna Pharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Dicerna Pharmaceuticals Margin History

Dicerna Pharmaceuticals Gross marginDicerna Pharmaceuticals Profit marginDicerna Pharmaceuticals EBIT marginDicerna Pharmaceuticals Profit margin
2025e0 %-67.19 %-65.96 %
2024e0 %-93.77 %-87.28 %
2023e0 %-130.85 %-115.49 %
2022e0 %-81.18 %-75.2 %
2021e0 %-76.2 %-71.33 %
20200 %-68.9 %-68.59 %
20190 %-536.4 %-504.18 %
20180 %-988.71 %-1,433.87 %
20170 %-5,170 %-6,020 %
20160 %-19,900 %-19,833.33 %
20150 %-31,500 %-31,400 %
20140 %0 %0 %
20130 %0 %0 %
20120 %-132.86 %-144.29 %
20110 %-96.2 %-108.86 %

Dicerna Pharmaceuticals Aktienanalyse

What does Dicerna Pharmaceuticals do?

Dicerna Pharmaceuticals Inc. is a biopharmaceutical company based in the United States that focuses on RNA interference (RNAi). It was founded in 2007 and is headquartered in Lexington, Massachusetts. It also has branches in Germany and Switzerland. Dicerna Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Revenue Details

Understanding Dicerna Pharmaceuticals's Sales Figures

The sales figures of Dicerna Pharmaceuticals originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing Dicerna Pharmaceuticals’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize Dicerna Pharmaceuticals's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in Dicerna Pharmaceuticals’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about Dicerna Pharmaceuticals stock

How much revenue did Dicerna Pharmaceuticals generate this year?

Dicerna Pharmaceuticals has achieved a revenue of 170.98 M USD this year.

How much was the turnover of the company Dicerna Pharmaceuticals compared to the previous year?

The revenue of Dicerna Pharmaceuticals has increased by -2.8% decreased compared to the previous year.

What does revenue mean for investors?

The revenue of a company is an important indicator of its financial performance and attractiveness for investors.

Which factors influence the revenue of Dicerna Pharmaceuticals?

The revenue of Dicerna Pharmaceuticals is influenced by various factors, including the demand for its products and services, market conditions, and prices.

How is the revenue of Dicerna Pharmaceuticals measured?

Revenue is typically measured in units referring to the sale of goods and services provided by the company.

How does an increase in sales affect investments?

An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.

What are the possible risks associated with a declining revenue?

A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.

Why is the sales revenue of Dicerna Pharmaceuticals so important for investors?

The revenue of Dicerna Pharmaceuticals is an important indicator of financial performance and attractiveness for investors.

What strategic measures can a company take to increase revenue?

A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.

How much dividend does Dicerna Pharmaceuticals pay?

Over the past 12 months, Dicerna Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Dicerna Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Dicerna Pharmaceuticals?

The current dividend yield of Dicerna Pharmaceuticals is .

When does Dicerna Pharmaceuticals pay dividends?

Dicerna Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Dicerna Pharmaceuticals?

Dicerna Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Dicerna Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Dicerna Pharmaceuticals located?

Dicerna Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Dicerna Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Dicerna Pharmaceuticals from 11/27/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/27/2024.

When did Dicerna Pharmaceuticals pay the last dividend?

The last dividend was paid out on 11/27/2024.

What was the dividend of Dicerna Pharmaceuticals in the year 2023?

In the year 2023, Dicerna Pharmaceuticals distributed 0 USD as dividends.

In which currency does Dicerna Pharmaceuticals pay out the dividend?

The dividends of Dicerna Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Dicerna Pharmaceuticals stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Dicerna Pharmaceuticals

Our stock analysis for Dicerna Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Dicerna Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.